Action of celecoxib on hepatic metabolic changes induced by the Walker-256 tumour in rats

Basic and Clinical Pharmacology and Toxicology

Volumn 101, Issue 5, 2007, Pages 294-300

  Acco, Alexandra ^b   Da Rocha Alves Da Silva, Mário Henrique ^a   Batista, Márcia Regina ^a   Yamamoto, Nair Seiko ^a   Bracht, Adelar ^a  

^a STATE UNIVERSITY OF MARINGÁ   (Brazil)

^b FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ARGININE; CELECOXIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; GLUCONEOGENESIS; GLUCOSE UTILIZATION; GLYCOLYSIS; ISOLATED LIVER; LIVER METABOLISM; LIVER PERFUSION; MALE; NONHUMAN; OXYGEN CONSUMPTION; PRIORITY JOURNAL; RAT; TUMOR CELL; TUMOR GROWTH; UREA CYCLE; WALKER CARCINOMA; WEIGHT GAIN;

ALANINE; AMMONIA; ANIMALS; ARGININE; CARCINOMA 256, WALKER; CYCLOOXYGENASE 2 INHIBITORS; GLUCONEOGENESIS; GLYCOLYSIS; LIVER; MALE; NEOPLASM TRANSPLANTATION; PERFUSION; PYRAZOLES; RATS; SULFONAMIDES; UREA;

ANIMALIA; RATTUS;

EID: 34848838384     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2007.00124.x     Document Type: Article

References (40)

1. Giglio A. Resistência à quimioterapia: uma revisão para o oncologista. Rev Soc Bras Cancerol 2001 14 : 32 8.
2. Davis TW, Zweifel BS, O'Neal JM et al. Inhibition of cyclooxygenase-2 by celecoxib reverses tumor-induced wasting. J Pharmacol Exp Ther 2004 308 : 929 34.
3. Wenger FA, Kilian M, Bisevac M et al. Effects of Celebrex and Zyflo on liver metastasis and lipid peroxidation in pancreatic cancer in Syrian hamsters. Clin Exp Metastasis 2002 19 : 681 7.
4. Cerchietti LC, Naviganti AH, Peluffo GD et al. Effects of celecoxib, medroxyprogesterone, and dietary intervention on systemic syndromes in patients with advanced lung adenocarcinoma: a pilot study. J Pain Symptom Manage 2004 27 : 85 95.
5. Niitsu Y, Takayama T, Miyanishi K et al. Chemoprevention of colorectal cancer. Cancer Chemother Pharmacol 2004 54 : S40 3.
6. Basu GD, Pathangey LB, Tinder TL, LaGioia M, Gendler SJ, Mukherjee P. Cox-2 inhibitor induces apoptosis in breast cancer cells in an in vivo model of spontaneous metastatic breast cancer. Mol Cancer Res 2004 2 : 632 42.
7. Park K, Yang JH, Choi Y, Lee C, Kim SY, Byun Y. Chemoprevention of 4-NQO-induced oral carcinogenesis by co-administration of all-trans retinoic acid loaded microspheres and celecoxib. J Control Release 2005 104 : 167 79.
8. Ganswindt U, Budach W, Jendrossek V, Becker G, Bamberg M, Belka C. Combination of celecoxib with percutaneous radio-therapy in patients with localized prostate cancer - a phase I study. Radiat Oncol 2006 1 : 9.
9. Harris RE, Beebe-Donk J, Alshafie G. Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors. BMC Cancer 2006 6 : 27.
10. Arellanes-Robledo J, Marquez-Rosado L, Perez-Carreon JI, Fattel-Fazenda S, Aguirre-Garcia J, Villa-Trevino S. Celecoxib induces regression of putative preneoplastic lesions in rat liver. Anticancer Res 2006 26 : 1271 80.
11. Arber N, Eagle CJ, Spicak J et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006 355 : 885 95.
12. Backhus LM, Sievers E, Lin GY et al. Perioperative cyclooxygenase-2 inhibition to reduce tumor cell adhesion and metastatic potential of circulating tumor cells in non-small cell lung cancer. J Thorac Cardiovasc Surg 2006 132 : 297 303.
13. Corbello-Pereira SR, Danrronqui E, Constantin J, Silva MHR, Yamamoto NS, Bracht A. The urea cycle and related pathways in the liver of Walker-256 tumor-bearing rats. Biochim Biophys Acta 2004 1688 : 187 96.
14. Vicentino C, Constantin J, Stecanella L, Bracht A, Yamamoto NS. Glucose and glycogen catabolism in perfused livers of Walker-256 tumor-bearing rats and the response to hormones. Pathophysiology 2002 8 : 175 82.
15. Tisdale MJ. Metabolic abnormalities in cachexia and anorexia. Nutrition 2000 16 : 1013 4.
16. Vicentino C, Constantin J, Bracht A, Yamamoto NS. Long-chain fatty acid uptake and oxidation in the perfused liver of Walker-256 tumour-bearing rats. Liver 2002 22 : 342 50.
17. Scholz R, Bücher T. Hemoglobin-free perfusion of rat liver. In : Chance B, Estabrook RW, Williamson JR (eds). Control of Energy Metabolism. Academic Press, New York, 1965 393 414.
18. Bergmeyer HU. Methods of Enzymatic Analysis. Verlag Chemie-Academic Press, Weinheim, London, 1974.
19. Bracht A, Ishii-Iwamoto EL, Kelmer-Bracht AM. O estudo do metabolismo no fígado em perfusão. In : Bracht A, Ishii-Iwamoto EL (eds). Métodos de Labora-tório em Bioquímica. Editora Manole, São Paulo, Brazil, 2003 275 89.
20. Sies H. Nicotinamide nucleotide compartmentation. In : Sies H (ed.). Metabolic Compartmentation. Academic Press, New York, 1982 205 31.
21. Kimmig R, Mauch TJ, Kerzl W, Schwabe U, Scholz R. Actions of glucagon on flux rates in perfused rat liver. I. Kinetics of the inhibitory effect on glycolysis and the stimulatory effect on glycogenolysis. Eur J Biochem 1983 136 : 609 16.
22. Basu GD, Pathangey LB, Tinder TL, Gendler SJ, Mukherjee P. Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells. Breast Cancer Res 2005 7 : R422 35.
23. Ayalasomayajula SP, Kompella UB. Celecoxib, a selective cyclooxygenase-2 inhibitor, inhibits retinal vascular endothelial growth factor expression and vascular leakage in a streptozotocin-induced diabetic rat model. Eur J Pharmacol 2004 458 : 283 9.
24. Maddrey WC, Maurath CJ, Verburg KM, Geis GS. The hepatic safety and tolerability of the novel cyclooxygenase-2 inhibitor celecoxib. Am J Ther 2000 7 : 151 2.
25. Garnett WR. Clinical implications of drug interactions with coxibs. Pharmacotherapy 2001 21 : 1223 32.
26. Fosslien E. Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia. Crit Rev Clin Lab Sci 2000 37 : 431 502.
27. Gonzalez-Ortiz M, Martinez-Abundis E, Balcazar-Munoz BR, Robles-Cervantes JA. Inhibition of cyclooxygenase-1 or -2 on insulin sensitivity in healthy subjects. Horm Metab Res 2001 33 : 250 3.
28. Jendrossek V, Handrick R, Belka C. Celecoxib activates a novel mitochondrial apoptosis signaling pathway. FASEB J 2003 17 : 1547 49.
29. Riedl K, Krysan K, Pold M et al. Multifaceted roles of cyclooxygenase-2 in lung cancer. Drug Resist Updat 2004 7 : 169 84.
30. Maier TJ, Janssen A, Schmidt R, Geisslinger G, Grosch S. Targeting the beta-catenin/APC pathway: a novel mechanism to explain the cyclooxygenase-2- independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. FASEB J 2005 19 : 1353 55.
31. Pan M, Choudry HA, Epler MJ et al. Arginine transport in catabolic disease states. J Nutr 2004 134 : 2826S 9S.
32. Morris-Jr SM. Regulation of enzymes of the urea cycle and arginine metabolism. Annu Rev Nutr 2002 22 : 87 105.
33. Bachrach U. Polyamines and cancer: minireview article. Amino Acids 2004 26 : 307 309.
34. Sharma RA, Manso MM, Gescher A, Steward WP. Colorectal cancer chemoprevention: biochemical targets and clinical development of promising agents. Eur J Cancer 2001 371 : 12 22.
35. Yamazaki R, Kusunoki N, Matsuzaki T, Hashimoto S, Kawai S. Selective cyclooxygenase-2 inhibitors show a differential ability to inhibit proliferation and induce apoptosis of colon adenocarcinoma cells. FEBS Lett 2002 531 : 278 84.
36. Cui W, Yu CH, Hu KQ. In vitro and in vivo effects and mechanisms of celecoxib-induced growth inhibition of human hepatocellular carcinoma cells. Clin Cancer Res 2005 11 : 8213 21.
37. Kern MA, Haugg AM, Koch AF et al. Cyclooxygenase-2 inhibition induces apoptosis signaling via death receptors and mitochondria in hepatocellular carcinoma. Cancer Res 2006 66 : 7059 66.
38. Sakoguchi-Okada N, Takahashi-Yanaga F, Fukada K et al. Celecoxib inhibits the expression of survivin via the suppression of promoter activity in human colon cancer cells. Biochem Pharmacol 2007 73 : 1318 29.
39. Tong Z, Wu X, Chen CS, Kehrer JP. Cytotoxicity of a non-cyclooxygenase-2 inhibitory derivative of celecoxib in non-small-cell lung cancer A549 cells. Lung Cancer 2007 52 : 117 24.
40. Okada H, Mak TW. Pathways of apoptotic and non-apoptotic death in tumour cells. Nat Rev Cancer 2004 4 : 592 603.